BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript [Seeking Alpha]
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Follow Q2: 2024-08-06 Earnings Summary Play Call Press Release 10-Q EPS of -$0.21 beats by $0.57 | Revenue of $1.10M (141.58% Y/Y) beats by $4,000.00 BioXcel Therapeutics, Inc. ( NASDAQ: BTAI ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer Richard Steinhart - Senior Vice President and Chief Financial Officer Matt Wiley - Senior Vice President and Chief Commercial Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Raghuram Selvaraju - H.C. Wainwright Operator Good morning, and welcome to the BioXcel Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. After the formal remarks, there will be a question-and-answer session. [Operator Instructions]. Just to remind everyone,
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationGlobeNewswire
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaGlobeNewswire
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $7.00 price target on the stock.MarketBeat
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its price target lowered by analysts at UBS Group AG from $3.50 to $1.00. They now have a "neutral" rating on the stock.MarketBeat
BTAI
Earnings
- 8/6/24 - Beat
BTAI
Sec Filings
- 9/19/24 - Form 8-K
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- BTAI's page on the SEC website